Please consider adding your organization to a letter we will be sending to the Centers for Medicare and Medicaid Services (CMS) next week, encouraging the agency to revise its proposed rule on Medicaid “line extension” rebates and exclude orphan drugs from the scope of this policy.
This discretionary decision would greatly encourage the development of new treatments for rare diseases, while maintaining the intent and appropriate scope of the line extension rebate. We are greatly concerned that failure to remove orphan drugs from the scope of the policy will result in creation of an economic barrier to rare disease therapeutic innovation in conflict with the Orphan Drug Act.
A two-page summary of the issue is available here: Line Extension Patient Group Letter
The patient group sign-on is available here: Line Extension Two-Pager_community sign on
Please contact Carrie Ostrea at email@example.com by Monday, March 31 to add your organization to the letter.